Mark D. Tyson II, MD, MPH, discusses findings from the phse 3b PATAPSCO study, evaluating durvalumab plus BCG for patients with BCG-naïve, high-risk NMIBC. PATAPSCO was designed as a US-based ...
FDA Breakthrough Device Designation was granted to an AI-powered H&E-based prognostic assay for bladder cancer, described as the first such designation in this disease setting. Proprietary foundation ...
In this video, recorded at the 2026 American Urological Association Annual Meeting in Washington, DC, Murilo De Almeida Luz, MD, gives an overview of the DAROL study design and key findings.
EMBARK enrolled 1068 men with high-risk BCR post-local therapy, conventional-imaging M0 status, PSA ≥1 ng/mL post-prostatectomy or ≥2 ng/mL above post-EBRT nadir, and PSADT ≤9 months. A protocolized ...
Michael S. Cookson, MD, MMHC, FACS, unpacks the significance of the phase 2 ARASEC trial evaluating darolutamide in mHSPC. The novel hybrid design used in the phase 2 ARASEC trial (NCT05059236) 1 —and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results